I am a physician-scientist whose clinical focus is treating patients with hematologic malignancies, and I have particular expertise in allogeneic (donor-derived) hematopoietic stem cell transplantation for patients with leukemia, lymphoma, myelodysplastic syndrome, and multiple myeloma. At Memorial Sloan Kettering Cancer Center, we are pioneering a new type of stem cell transplantation in which we remove a specific subset of cells (T cells) from the donor’s stem cells before the transplant; this significantly reduces the so-called graft-versus-host reactions. As the principle investigator, I am leading clinical trials to study the effectiveness of T cell-depleted transplants from related and unrelated donors in patients with high-risk multiple myeloma.
My research has focused on ways to reduce rates of disease recurrence following allogeneic stem cell transplantations. In particular, I am developing specific donor-derived immune cells (T lymphocytes) to treat both the viral complications of transplantation and disease relapse following transplantation. This treatment approach has been termed “adoptive immunotherapy” and we are testing it in several active clinical trials here at Memorial Sloan Kettering.
In my function as the Medical Director of the Cytotherapy Laboratory (Bone Marrow Transplantation Laboratory), I am establishing new T cell depletion techniques and other methods to manipulate donor stem cell products that will optimize patients’ outcomes.
- Clinical Expertise: Hematologic Malignancies (Leukemia, Multiple Myeloma, MDS); Allogeneic Bone Marrow Transplantation; Immunotherapy; Cancer Vaccines
- Languages Spoken: English
- Education: MD, PhD, Medical University of Hamburg (Germany)
- Residencies: Medical University of Hamburg (Germany); Rush University Medical Center (Chicago)
- Fellowships: Memorial Sloan Kettering Cancer Center
- Board Certifications: Internal Medicine; Medical Oncology
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Led by Guenther Koehne
- A Phase I Study of WT1-Specific Donor-Derived T Cells in Patients with Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia after T-Cell-Depleted Allogeneic Stem Cell Transplantation
- A Phase II Study of Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post-Transplantation Donor Lymphocyte Infusions for Patients with Relapsed or High-Risk Multiple Myeloma
- A Pilot Study of the Wilms' Tumor 1 (WT1) Analog Peptide Vaccine in Patients with Multiple Myeloma after Autologous Stem Cell Transplantation
Clinical Trials Co-Investigated by Guenther Koehne
- A Phase II Study of CMV-Immune T cells for the Treatment of Cytomegalovirus Infection after Stem Cell Transplantation
- A Phase II Study of CMV-Immune T cells from a Third Party for the Treatment of Cytomegalovirus Infection after Allogeneic Stem Cell Transplantation
- A Phase II Trial of Transplants from HLA-Compatible Donors with T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System for the Treatment of Patients with Hematologic Malignancies and Disorders
- Transplantation of Unrelated Donor Double-Unit Cord Blood with T-Cell-Depleted Stem Cells for Patients with High-Risk Hematologic Cancers
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more